Exelixis, Inc. (0IJO.L)
USD 34.24
(-1.28%)
USD 34.24
(-1.28%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 189.94 Million USD | -0.12% |
| 2022 | 190.17 Million USD | 270.9% |
| 2021 | 51.27 Million USD | 4.45% |
| 2020 | 49.08 Million USD | 2.24% |
| 2019 | 48.01 Million USD | 294.24% |
| 2018 | 12.17 Million USD | -16.19% |
| 2017 | 14.53 Million USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 381.43 Million USD | 45.37% |
| 2014 | 262.39 Million USD | -21.78% |
| 2013 | 335.47 Million USD | 4.0% |
| 2012 | 322.56 Million USD | 82.61% |
| 2011 | 176.64 Million USD | 3.48% |
| 2010 | 170.71 Million USD | 322.94% |
| 2009 | 40.36 Million USD | -45.98% |
| 2008 | 74.71 Million USD | -29.34% |
| 2007 | 105.74 Million USD | -2.15% |
| 2006 | 108.07 Million USD | 1.14% |
| 2005 | 106.85 Million USD | -21.71% |
| 2004 | 136.49 Million USD | 34.84% |
| 2003 | 101.22 Million USD | 55.13% |
| 2002 | 65.25 Million USD | 56.12% |
| 2001 | 41.79 Million USD | 424.02% |
| 2000 | 7.97 Million USD | -27.49% |
| 1999 | 11 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 198.01 Million USD | 0.0% |
| 2024 Q3 | 194.44 Million USD | 0.0% |
| 2024 Q1 | 201.46 Million USD | 0.0% |
| 2023 Q3 | 190.85 Million USD | -1.97% |
| 2023 FY | 189.94 Million USD | -0.12% |
| 2023 Q1 | 186.94 Million USD | -1.69% |
| 2023 Q2 | 194.69 Million USD | 4.14% |
| 2023 Q4 | 189.94 Million USD | -0.48% |
| 2022 Q3 | 159.83 Million USD | -0.73% |
| 2022 Q2 | 161.01 Million USD | 217.99% |
| 2022 FY | 190.17 Million USD | 270.9% |
| 2022 Q1 | 50.63 Million USD | -1.24% |
| 2022 Q4 | 190.17 Million USD | 18.98% |
| 2021 Q2 | 53.22 Million USD | 0.73% |
| 2021 Q1 | 52.83 Million USD | 7.64% |
| 2021 FY | 51.27 Million USD | 4.45% |
| 2021 Q4 | 51.27 Million USD | -1.88% |
| 2021 Q3 | 52.25 Million USD | -1.82% |
| 2020 Q4 | 49.08 Million USD | 3.07% |
| 2020 Q1 | 47.88 Million USD | -0.27% |
| 2020 Q2 | 48.33 Million USD | 0.94% |
| 2020 Q3 | 47.62 Million USD | -1.46% |
| 2020 FY | 49.08 Million USD | 2.24% |
| 2019 Q1 | 19.95 Million USD | 63.89% |
| 2019 FY | 48.01 Million USD | 294.24% |
| 2019 Q4 | 48.01 Million USD | 102.54% |
| 2019 Q3 | 23.7 Million USD | 5.15% |
| 2019 Q2 | 22.54 Million USD | 12.95% |
| 2018 Q4 | 12.17 Million USD | -3.49% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q3 | 12.61 Million USD | -38.88% |
| 2018 FY | 12.17 Million USD | -16.19% |
| 2018 Q2 | 20.64 Million USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | 14.53 Million USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | 14.53 Million USD | 0.0% |
| 2016 Q2 | 288.55 Million USD | -20.1% |
| 2016 Q4 | - USD | -100.0% |
| 2016 Q1 | 361.15 Million USD | -5.32% |
| 2016 Q3 | 81.49 Million USD | -71.76% |
| 2016 FY | - USD | -100.0% |
| 2015 Q1 | 364.35 Million USD | 38.86% |
| 2015 FY | 381.43 Million USD | 45.37% |
| 2015 Q4 | 381.43 Million USD | 1.06% |
| 2015 Q3 | 377.43 Million USD | 1.67% |
| 2015 Q2 | 371.22 Million USD | 1.89% |
| 2014 Q1 | 341.62 Million USD | 1.83% |
| 2014 Q3 | 257.96 Million USD | 1.68% |
| 2014 Q2 | 253.69 Million USD | -25.74% |
| 2014 FY | 262.39 Million USD | -21.78% |
| 2014 Q4 | 262.39 Million USD | 1.72% |
| 2013 Q1 | 317.99 Million USD | -1.42% |
| 2013 Q4 | 335.47 Million USD | 1.82% |
| 2013 Q3 | 329.46 Million USD | 1.81% |
| 2013 Q2 | 323.59 Million USD | 1.76% |
| 2013 FY | 335.47 Million USD | 4.0% |
| 2012 Q2 | 169.54 Million USD | 0.89% |
| 2012 Q3 | 322.12 Million USD | 90.0% |
| 2012 FY | 322.56 Million USD | 82.61% |
| 2012 Q4 | 322.56 Million USD | 0.14% |
| 2012 Q1 | 168.04 Million USD | -4.87% |
| 2011 FY | 176.64 Million USD | 3.48% |
| 2011 Q3 | 175.08 Million USD | 0.7% |
| 2011 Q4 | 176.64 Million USD | 0.89% |
| 2011 Q2 | 173.86 Million USD | 1.64% |
| 2011 Q1 | 171.06 Million USD | 0.21% |
| 2010 Q3 | 197.85 Million USD | -0.23% |
| 2010 Q1 | 38.4 Million USD | -4.86% |
| 2010 Q2 | 198.32 Million USD | 416.44% |
| 2010 Q4 | 170.71 Million USD | -13.72% |
| 2010 FY | 170.71 Million USD | 322.94% |
| 2009 Q1 | 71.78 Million USD | -3.93% |
| 2009 Q2 | 69.35 Million USD | -3.38% |
| 2009 Q3 | 66.92 Million USD | -3.5% |
| 2009 Q4 | 40.36 Million USD | -39.69% |
| 2009 FY | 40.36 Million USD | -45.98% |
| 2008 Q1 | 102.93 Million USD | -2.66% |
| 2008 FY | 74.71 Million USD | -29.34% |
| 2008 Q4 | 74.71 Million USD | -29.8% |
| 2008 Q3 | 106.43 Million USD | -3.33% |
| 2008 Q2 | 110.09 Million USD | 6.95% |
| 2007 Q1 | 105.63 Million USD | -2.26% |
| 2007 Q4 | 105.74 Million USD | 5.92% |
| 2007 Q3 | 99.84 Million USD | -2.8% |
| 2007 FY | 105.74 Million USD | -2.15% |
| 2007 Q2 | 102.71 Million USD | -2.76% |
| 2006 Q4 | 108.07 Million USD | 7.04% |
| 2006 Q1 | 106.25 Million USD | -0.57% |
| 2006 Q3 | 100.96 Million USD | -2.26% |
| 2006 Q2 | 103.3 Million USD | -2.78% |
| 2006 FY | 108.07 Million USD | 1.14% |
| 2005 Q4 | 106.85 Million USD | 2.09% |
| 2005 Q1 | 133.64 Million USD | -2.09% |
| 2005 FY | 106.85 Million USD | -21.71% |
| 2005 Q3 | 104.67 Million USD | -2.52% |
| 2005 Q2 | 107.38 Million USD | -19.65% |
| 2004 FY | 136.49 Million USD | 34.84% |
| 2004 Q1 | 99.4 Million USD | -1.8% |
| 2004 Q2 | 98.89 Million USD | -0.51% |
| 2004 Q3 | 103.08 Million USD | 4.24% |
| 2004 Q4 | 136.49 Million USD | 32.41% |
| 2003 Q3 | 69.3 Million USD | 4.05% |
| 2003 FY | 101.22 Million USD | 55.13% |
| 2003 Q2 | 66.6 Million USD | 3.01% |
| 2003 Q1 | 64.65 Million USD | -0.92% |
| 2003 Q4 | 101.22 Million USD | 46.07% |
| 2002 Q2 | 41.6 Million USD | -0.23% |
| 2002 FY | 65.25 Million USD | 56.12% |
| 2002 Q1 | 41.69 Million USD | -0.23% |
| 2002 Q3 | 41.36 Million USD | -0.56% |
| 2002 Q4 | 65.25 Million USD | 57.75% |
| 2001 Q1 | 6.76 Million USD | -15.16% |
| 2001 Q3 | 40.7 Million USD | 2.01% |
| 2001 Q4 | 41.79 Million USD | 2.67% |
| 2001 FY | 41.79 Million USD | 424.02% |
| 2001 Q2 | 39.9 Million USD | 489.71% |
| 2000 Q3 | 5.97 Million USD | -40.39% |
| 2000 Q4 | 7.97 Million USD | 33.53% |
| 2000 FY | 7.97 Million USD | -27.49% |
| 2000 Q1 | 10.47 Million USD | 0.0% |
| 2000 Q2 | 10.02 Million USD | -4.32% |
| 1999 FY | 11 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -679.353% |
| Dynavax Technologies Corporation | 252.41 Million USD | 24.75% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -472.189% |
| Perrigo Company plc | 3.63 Billion USD | 94.771% |
| Illumina, Inc. | 1.48 Billion USD | 87.244% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.393% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -18894.4% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 97.639% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 98.534% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -9.318% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 92.973% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -706.933% |
| Waters Corporation | 2.3 Billion USD | 91.761% |
| Biogen Inc. | 7.18 Billion USD | 97.358% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -466.743% |
| Evolus, Inc. | 120.35 Million USD | -57.815% |
| Adicet Bio, Inc. | 17.7 Million USD | -972.948% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -412.268% |
| bluebird bio, Inc. | 224.41 Million USD | 15.362% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 62.128% |
| FibroGen, Inc. | 89.69 Million USD | -111.762% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 93.055% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -5764.947% |
| Homology Medicines, Inc. | 43.17 Million USD | -339.93% |
| Geron Corporation | 35.05 Million USD | -441.908% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 91.893% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 51.027% |
| Myriad Genetics, Inc. | 130.9 Million USD | -45.106% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -20193.162% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -96.331% |
| Zoetis Inc. | 6.56 Billion USD | 97.106% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -4214.948% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 90.385% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 67.974% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 73.79% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -455.554% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 86.436% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -315.696% |
| Verastem, Inc. | 40.08 Million USD | -373.841% |
| Nektar Therapeutics | 112.62 Million USD | -68.652% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -6.668% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -6079.05% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 83.228% |
| OPKO Health, Inc. | 222.03 Million USD | 14.453% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 26.464% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | -46.038% |
| Imunon, Inc. | 1.13 Million USD | -16572.094% |
| Blueprint Medicines Corporation | 610.96 Million USD | 68.911% |
| Insmed Incorporated | 1.19 Billion USD | 84.083% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 87.331% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -233.305% |
| TG Therapeutics, Inc. | 100.11 Million USD | -89.72% |
| Incyte Corporation | 29.16 Million USD | -551.341% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 57.459% |